



Patient metric data collection form for **ESTABLISHED** rheumatoid arthritis (RA)

Please use the correct form. There are separate forms for **ESTABLISHED** and **RECENT ONSET** patients

This data collection form is for use *only* in RA patients with **ESTABLISHED** disease (i.e. patients >2 years from diagnosis)

Please review and complete every question

PLEASE COMPLETE ALL SECTIONS

UNIT AND PATIENT DETAILS							
Q1	Unit (name).....						
	Age (circle applicable)	<30 years	30–40 years	41–50 years	51–60 years	61–70 years	>70 years
	Gender (circle applicable)	Male	Female				
	Duration of disease (circle applicable)	2–5 years	6–10 years	>10 years			
DISEASE ACTIVITY ASSESSMENT							
Q2	Criteria	Yes	No	Not clinically relevant			
2.1	Does the patient have high/moderate disease activity according to DAS28 score? ¹⁻³	<input type="checkbox"/>	<input type="checkbox"/>				
<i>If you answered 'Yes' to question 2.1, please go to question 2.3</i>							
2.2	Is the patient in sustained low disease activity [DAS28 <3.2] or remission [DAS28 ≤2.6]? ¹⁻³	<input type="checkbox"/>	<input type="checkbox"/>				
<i>If you answered 'Yes' to question 2.2, please go to question 2.4</i>							
2.3	Has the patient received regular DAS28 assessment every 4–6 weeks? ¹⁻³	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			
<i>If you answered 'Yes' to question 2.3, please go to question 3 on the next page</i>							
2.4	Has the patient received DAS28 assessment at every visit? ¹⁻³	<input type="checkbox"/>	<input type="checkbox"/>				
<i>If 'No', please briefly explain why then go to question 3 on the next page</i>							

PLEASE COMPLETE **ALL** SECTIONS

TREATMENT MODIFICATION					
Q3	Criteria	Yes		No	
3.1	Has the patient received regular (at least every 3 months) treatment modification in line with NICE guidance ⁴ ?	<input type="checkbox"/>		<input type="checkbox"/>	
3.2	Has the patient achieved sustained low disease activity [DAS28 <3.2] or remission (DAS28 ≤2.6) ¹⁻³ ?	<input type="checkbox"/>		<input type="checkbox"/>	
3.3	Is the patient on biologics?	<input type="checkbox"/>		<input type="checkbox"/>	
<i>If you answered 'No' to question 3.3, please go to question 4 on the next page</i>					
		Yes		No	
3.4	Has the patient achieved an adequate response within the first 6 months of initiating therapy (an improvement in DAS28 of 1.2 points or more) in line with NICE guidance ⁴ ?	<input type="checkbox"/>		<input type="checkbox"/>	
				Patient on biologics for <6 months	
		<input type="checkbox"/>		<input type="checkbox"/>	
<i>If you answered 'Yes ' or 'Patient on biologics for <6 months' to question 3.4, please go to question 4 on the next page</i>					
		Yes	No	Patient on biologics for <6 months	Active clinical decision not to do so
3.5	If the patient has NOT achieved a timely improvement in DAS28 of 1.2 points or more, has the patient been moved to the next treatment in the pathway according to NICE guidance ⁴⁻⁶ ?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PLEASE COMPLETE ALL SECTIONS

ANNUAL REVIEW [#]				
<i>Is it <u>CLEARLY DOCUMENTED</u> that the following actions have been carried out within the <u>LAST 12 MONTHS</u>:</i>				
Q4	Criteria	Yes	No	
4.1	Damage has been assessed, and functional ability measured (using, for example, the Health Assessment Questionnaire [HAQ])?	<input type="checkbox"/>	<input type="checkbox"/>	
4.2	The patient has been checked for the development of comorbidities (e.g., hypertension, ischaemic heart disease, osteoporosis, depression)?	<input type="checkbox"/>	<input type="checkbox"/>	
4.3	There was assessment of symptoms that suggest complications (e.g., vasculitis and disease of the cervical spine, lung, eyes)?	<input type="checkbox"/>	<input type="checkbox"/>	
4.4	Appropriate cross referral within the multidisciplinary team was organised?	<input type="checkbox"/>	<input type="checkbox"/>	
4.5	The need for referral for surgery was assessed?	<input type="checkbox"/>	<input type="checkbox"/>	
4.6	The patient has been asked about the impact of RA on their day-to-day experience of life (e.g. employment, social, sexual, functional activities of daily living)?	<input type="checkbox"/>	<input type="checkbox"/>	

[#]NICE recommend an ‘annual review’ with each RA patient (NICE clinical guideline 79 – Rheumatoid arthritis: section 1.5.1.4)

References

¹Wells et al. Ann Rheum Dis 2009;68:954–960. In this paper DAS28 <2.6 is defined as the ‘threshold for remission’. ²Smolen et al. Ann Rheum Dis 2010; 69:631–7. ³Gülfe et al. BMC Musculoskeletal Disorders 2009;10:41. Definition of high disease activity=DAS28 >5.1; definition of moderate disease activity=DAS28 <5.1; definition of low disease activity=DAS28 <3.2.

⁴NICE clinical guideline 79 – Rheumatoid arthritis. Available at: www.nice.org.uk/nicemedia/pdf/CG79NICEGuideline.pdf (accessed August 2010).

⁵NICE technology appraisal guidance 195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. Available at: <http://guidance.nice.org.uk/TA195/Guidance/pdf/English> (accessed September 2010).

⁶NICE technology appraisal guidance 198: Tocilizumab for the treatment of rheumatoid arthritis. Available at: <http://guidance.nice.org.uk/TA198/Guidance/pdf/English> (accessed September 2010). Section 1.1.

If you have any queries please contact CQRA (email cqra@nras.org.uk)